Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 repersons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/028,075			
Filing Date	12/21/2001			
First Named Inventor	Khan et al.			
Group Art Unit	To be assigned 1636			
Examiner Name	To be assigned J. Dunston			
Attorney Docket Number	2183-5223US			

					U.S. PATENT DOCU	MENTS		
Examiner Initials *	Cite No.1	U.S. Pa	Kind (Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Passages or R	Relevant
			. (if kno	wn)		MM-DD-YYYY	Figures Ap	
		0,919,	50+		Callo et al.	11-20-2001	Duplicate	Citatio
_ ,,								·
				L			0,90	A PARENO
							TIGIN (% .
							14	1.40.
								A CAO
								(E)
·							<u> </u>	
			-			· ·	 	
- · · · · · · · · · · · · · · · · · · ·								
							 	
							 	
	· ·							
								
		<u> </u>						

	FOREIGN PATENT DOCUMENTS							
Evenine	Cia-	For	eign Patent Do	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te
								
			<u> </u>					
			<u> </u>				· · · · · · · · · · · · · · · · · · ·	
				_				

عياليسالسيني			
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

FEB 2 1 2002

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08A (08-00)

Approved for use through T0/31/2002, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no pippons are required to respond to a collection of information unless it contains a valid OMB control number

Please type a plus sign (+) inside this box

& THAUS Substitute for form 1449A/PTO Complete if Known 10/028,075 **Application Number** INFORMATION DISCLOSURE Filing Date 12/21/2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. To be assigned 1636 Group Art Unit -(use as many sheets as necessary) To be assigned J. Dunston **Examiner Name** of 2 Sheet **Attorney Docket Number** 2183-5223US

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 168, The American Association of Immunologists, USA.	
	FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414.	
	MEDZHITOV, TolHike Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.	
		_
<u></u>		
		Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA. FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414. MEDZHITOV, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-

		The state of the s	
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

itler the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/028,075 **Application Number** December 21, 2001 Filing Date First Named Inventor Khan et al. To be assigned 1636 Group Art Unit To be assigned J. Dunston **Examiner Name** 2183-5223US Attorney Docket Number

(use as many sheets as necessary) of 2 Sheet

U.S. PATENT DOCUMENTS						
Examiner Cite		Document Number	Publication Date	Name of Patentee or Applicant of	P C-l 1: 113 P-1	
Initials *	No.'	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
_		US-				
		US-				
		US-	•			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
]		US-				
		US-				
		US-				

		FOREIGN P	ATENT DOCU	MENTS		
Examiner Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code' - Number' - Kind Code' (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Te
		WO 93/33617	11-20-1999	Erasmus Universiteit	Duplicate C	itati
JD/		WO 97/49721	12-31-1997	University of Maryland		
	ļ					
			+			
						
					 	
					 	
			1			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
			··· ··································

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known					
Application Number	10/028,075					
Filing Date	December 21, 2001					
First Named Inventor	Khan et al.					
Group Art Unit	To be assigned 1636					
Examiner Name	To be assigned J. Dunston					
Attorney Docket Mumber	2192 5222110					

 	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Cite Initials * No.1		(3), volume-issue memority, variance, value pages, volume-issue memority,					
/JD/		PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.					
		PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.					
		PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.					
		Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the subunits of human chorionic gonadotropin", AIDS 1997, Vol. 11, No. 11, pp.1333-1340.					
/JD/		Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, April 1998, Vol. 4, No. 4, pp. 428-434.	7				
		·					

Considered	Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
------------	-----------------------	---------------------------------	--------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attomey Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et. al.

Group Art Unit 1032 1636

Examiner Name T. McKelvey J. Dunston

2183-5223US

(use as many sheets as necessary)

Sheet 1 of 2

ubstitute for form 1449A/PTO

Examiner Cite Initials * No.	Document Number	Publication Date	Name of Patentee or Applicant of	Page Cohuma Lines When Delays	_
	 Number - Kind Code ² (if known)		. Cited Document	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear	elevant
/JD/	US- 4,977,244	12-11-1990	Muchmore et al.		
	US- 5,677,275	10-14-1007	Lunardi Iskanoar et al.	Duplicate Citat	cic
/JD/	US- 5,877,148	03-02-1999	Lunardi-Iskandar et al.		
	US- 5,958,413	09-28-1999	Anagnostopulos et al.		
	US- 5,997,871	12-07-1999	Gallo et al.		
	US- 6,319,504 B1	11-20-2001	Gallo et al.		
	US- 2003/0049273 A1	03-13-2003	Gallo et al.		
	US- 6,583,109 B1	06-24-2003	Gallo et al.		
	US- 6,596,688 B1	07-22-2003	Gallo et al.		
	US- 6,620,416 B1	09-16-2003	Gallo et al.		
	US- 2002/0064501	05-30-2002	Khan et al.		
	US- 2002/0041871	04-11-2002	Brudnak		
V	US-5,851,997	12-22-1998	Harris		
JD/	US- 6,489,296	12-03-2002	Grinnell et al.		

·····	<u>,</u>	FOREIGN P	ATENT DOCU	MENTS		
Examiner				Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*			Publication Date MM-DD-YYYY	Applicant of Cited Document		T 6
/JD/		EP 1 300 418	04-09-2003	Erasmus Universiteit Rotterdam		-
		WO 98/35691	08-20-1998	Proscript, Inc.		
		WO 02/085117	10-31-2002	Eisai Co., Ltd.		
		DE 3715662	11-19-1987	The Wellcome Foundation Ltd.		
		DE 19953339	: 05-17-2001	Goldham Pharma GmbH		
	,	WO 96/04008	02-15-1996	Government of the United States		
		WO 97/49373	12-31-1997	University of Maryland Biotechnology Institute		
V		WO 97/49418	12-31-1997	University of Maryland Biotechnology Institute		
/JD/		WO 97/49432	12-31-1997	University of Maryland Biotechnology Institute		-

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(;

+

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

ADE Stitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Application Number	10/028,075		
Filing Date	December 21, 2001		
First Named Inventor	Khan et. al.		
Group Art Unit	1632 1636		
Examiner Name	T. McKelvey J. Dunston		
Attorney Docket Number	2183-5223US		

	· -	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials * No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/JD/		CHRISTMAN et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target therapy, Intens Care Med, 1998, pp. 1131-38, Vol. 24.	
		JYONOUCHI et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-79, Vol. 120.	
		KANUNGO et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, Vol. 20.	
		ROHRIG et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, Vol. 289.	
		TAK et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, Vol. 107.	
		TAN et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.	
		TOVEY et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-21, Vol. 19.	
$\sqrt{}$		MUCHMORE et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.	
/JD/		MUCHMORE et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.	

Examiner	/ Jannifor Dunaton/ (05/19/2007)	Date	
Signature	/Jennifer Dunston/ (05/18/2007)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name T. McKelvey J. Dunston

Complete if Known

10/028,075

(use as many sheets as necessary)

Sheet 1 of 1

Attorney Docket Number 2183-5223US

Examiner Ci	Cite Document Number Pu		Publication Date	Name of Patentee or Applicant of	Deces Colores Line ND Date
Initials *		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JD/		US-5,380,668	01-10-1995	Herron	
1		US- 2003/0186244 A1	10-02-2003	Margus et al.	
		US- 2003/0113733 A1	06-19-2003	Khan et al.	
		US- 2003/0119720 A1	06-26-2003	Khan et al.	
		US- 2002/0064501 A1	05-30-2002	Khan et al.	
		US- 2003/0166556 A1	09-04-2003	Khan et al.	
		US- 2003/0215434 A1	11-20-2003	Khan et al.	
		US- 2003/0219425 A1	11-27-2003	Khan et al.	
		US- 2003/0220257 A1	11-27-2003	Benner et al.	
		US- 2003/0220258 A1	11-27-2003	Benner et al.	
		US- 2003/0220259 A1	11-27-2003	Benner et al.	
		US- 2003/0220260 A1	11-27-2003	Khan et al.	
		US- 2003/0220261 A1	11-27-2003	Khan et al.	
		US- 2003/0224995 A1	12-04-2003	Khan et al.	
JD/		US- 2004/0013661 A1	01-22-2004	Wensvoort et al.	
		US-			

Examiner Cite Initials* No.1	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	<u>_</u>
		Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ ⁶
/JD/		WO 03/029292 A2	04-10-2003	Erasmus Universiteit Rotterdam		

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO PADEMAN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

JUN 3 0 2006

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name T. McKelvey J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Sheet 1 of 2

U.S. PATENT DOCUMENTS Name of Patentee or Applicant of Document Number **Publication Date** Pages, Columns, Lines, Where Relevant Examiner Cite Cited Document MM-DD-YYYY Passages or Relevant Initials * No. Number - Kind Code² (if known) Figures Appear 7JD/ US-6,727,227 04-27-2004 Khavinson US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-US-

Examiner Initials*	Cite	Foreign Patent Document		Name of Patentee or	Pages, Cohmns, Lines,	
	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T6
, /JD/		WO 01/29067	04-26-2001	Obschestvo S Ogranichennoi Otvetstvennostiju "Klinika Instituta Bioregulyatsii I Gerontologii"		
		-	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

10/028,075 **Application Number**

(use as many sheets as necessary)

Sheet

Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1636
Examiner Name	T. McKelvey J. Dunston
Attorney Docket Number	2183-5223US

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ?			
/JD/		KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.				
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.				
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2004, pp. 503-506, Vol. 137, No. 5.				
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.				
		KHAVINSON et al., "Inductive Activity of Retinal Peptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.				
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	-			
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	*-			
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.				
$\sqrt{}$		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.				
/JD/		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	,			

Examiner	/Jennifer Dunston/ (05/18/2007)	Date]
Signature	7001111101 Dallototii (00/10/2007)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known	
Application Number	10/028,075	
Filing Date	December 21, 2001	
First Named Inventor	Khan et al.	
Group Art Unit	1636	
Examiner Name	J. Dunston	
Attorney Docket Number	2183-5223US	

(use as many sheets as necessary)
Sheet 1 of 3

Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Initials •	No.		MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
/JD/		US-2003/0148955	08-2003	Pluenneke	
		US- 4,427,660	01-1984	Schiffman et al.	
		US- 4,571,336	02-1986	Houck et al.	
		US- 4,753,965	06-1988	Stemerick et al.	
		US- 5,002,961	03-1991	Dage et al.	
		US- 5,223,397	06-1993	Pouletty	
		US- 5,801,193	09-1998	Ojo-Amaize et al.	· · · · · · · · · · · · · · · · · · ·
		US- 5,942,494	08-1999	Ginsberg et al.	
		US- 5,972,924	10-1999	Keep et al.	
		US- 6,051,596	04-2000	Badger	
		US- 6,075,150	06-2000	Wang et al.	
		US- 6,235,281	05-2001	Stenzel et al.	
		US- 6,310,041	10-2001	Haddox et al.	
W.		US- 6,630,138	10-2003	Gerlitz et al.	
JD/		US- 6,831,057	12-2004	Baldwin et al.	
		US-			
		US-			
	1	US-			

Where Relevant Passages or Relevant Figures Appear			Foreign Patent Document	Cite	
Veicaur Likmes which	Applicant of Cited Document	Publication Date MM-DD-YYYY	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	No.1	
	Thomas Jefferson University	08-1998	WO 98/34631 A1		/JD/
	Praecis Pharmaceuticals Incorporated et al.	11-2001	WO 2001/83554 A2		/JD/

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/028,075 INFORMATION DISCLOSURE December 21, 2001 Filing Date STATEMENT BY APPLICANT Khan et al. First Named Inventor **Group Art Unit** 1636 (use as many sheets as necessary) J. Dunston **Examiner Name** Sheet Attorney Docket Number 2183-5223US

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2			
/JD/		ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.				
		ADIB-CONQUY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.				
		ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.				
i		BAEUERLE et al., "Function and Activation of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.				
		BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaB Activation," The Journal of Neuroscience, I May 1998, pp. 3251-3260, Vol. 18, No. 9.				
		BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.				
		BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.				
		EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.				
		EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.				
$\sqrt{}$		FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliere's Clinical Haematology, 2000, 179-197, Vol. 13. No. 2.				
/JD/		JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y Acad. Sci., 2005, pp. 148-150, Vol. 1053.				

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Substitute for form 1449A/PTO

Sheet

		NON PATENT LITERATURE DOCUMENTS			
Examiner Cite Initials * No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/JD/		KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review, 2002, pp. 472-499, Vol. 7, No. 6.			
		KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.			
		LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.			
		MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.			
		MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.			
		MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.			
		NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.			
		SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.			
		TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.			
		WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neurophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.			
/JD/		YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	•		

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature	(Considered	J

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Sheet 1 of 2 Attorney Docket Number 2183-5

			U.S. PATENT D	OCUMENTS	
Examiner Initials *	Cite No.	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JD/	<u> </u>	US- 4,855,285	08-1989	Stevens	
		US- 5,994,126	11-1999	Steinman et al.	
		US- 6,150,500	11-2000	Salemo	
		US- 2004/0208885 A1	10-2004	Khan et al.	
V		US- 6,844,315	01-2005	Khan et al.	
JD/		US- 2005/0037430 A1	02-2005	Khan et al.	
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			
		US- `			
		US-			
_		US-			
		US-			
		US-			
		US-	-		
		US-			
		US-			
		US-			

		FOREIGN P	ATENT DOCUM	MENTS		
Examiner Initials*	Cite	Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	_Te
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
•			-			
			-			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered		
-----------------------	---------------------------------	--------------------	--	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 10/028,075 INFORMATION DISCLOSURE Filing Date December 21, 2001 STATEMENT BY APPLICANT First Named Inventor Khan et al. Group Art Unit 1636 (use as many sheets as necessary) **Examiner Name** J. Dunston Sheet 2183-5223US Attorney Docket Number

Examiner Cite Initials * No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/JD/		CUI et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, Vol. 286.			
		DWINNELL et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.			
		KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.	-		
		KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, Vol. 292.			
		Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551.			
		Merriam-Webster Medical Dictionary, 1994, p. 82.			
		MOAYERI et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.			
V		NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.			
/JD/		PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.			
			-		

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

DEC 11 2006

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name J. Dunston

(use as many sheets as necessary)

Sheet 1 of 3 14 Attorney Docket Number 2183-5223US

		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
xaminer Initials *	Cite No.	Number - Kind Code ² (if Incom)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
		US-2003/0148955	08-2003	Pluenneke	
		US- 4,427,660	01-1984	Schiffman et al.	
		US-4,571,336	02-1986	Houck et al.	
		US- 4,753,986	06-1988	Stemerick et al.	
		US- 5,002,961	03-1991	Dage et al.	
		US- 5,223,397	06-1993	Pouletty	
		US- 5,801,193	09-1998	Ojo-Amaize et al.	
		US- 5,942,494	06-1999	Ginsberg et al.	
		US- 5,972,924	10-1998	Keep et al.	
		US- 6,051,598	04-2000	Badger	
		US- 6,075,150	06-2000	Wang et al.	
		US- 6,235,281	05-2001	Stenzel et al.	
		US- 8,310,041	10-2001	Haddox et al.	
		US- 6,630,138	10-2003	Gerlitz et al.	
		US- 6,831,057	12-2004	Baldwin et al.	Duplicate Citati
		US-			
		US-			

	·	FUREIGIVE	ATENT DOCU		· · · · · · · · · · · · · · · · · · ·	
Examiner	Cite	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,	1
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 08/34631 A1	08-1998	Thomas Jefferson University		
		WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.	Duplicate Ci	tatio
	Ι					

		سوران بريان فينفض والوارية	
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known
THE OBJECT OF TH	Application Number	10/028,075
INFORMATION DISCLOSURE	Filing Date	December 21, 2001
STATEMENT BY APPLICANT	First Named Inventor	Khan et al.
	Group Art Unit	1636
(use as many sheets as necessary)	Examiner Name	J. Dunston
Sheet 2 of 3 14	Attorney Docket Number	2183-5223US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ,
		ARRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.	
		ADIB-CONQUY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharde Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.	
,		ARIMA et al., "IL-2-Indited Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.	
		BAEUERLE et al., "Function and Activation of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.	
		BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaß Activation," The Journal of Neuroscience, 1 May 1998, pp. 3251-3260, Vol. 18, No. 9.	
		BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.	
		BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.	
•	·	EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.	
		EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.	
		FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliet 's Clinical Haematology, 2000, 179-197, Vol. 13. No. 2.	
		JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y Acad. Sci., 2005, pp. 148-150, Vol. 1053.	·

			Duplicate Citations
Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/028,075 Application Number December 21, 2001 Filing Date Khan et al. First Named Inventor 1636 Group Art Unit J. Dunston **Examiner Name** 2183-5223US Attorney Docket Number

(use as many sheets as necessary) Sheet

		Cite	Circ	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Cohumns, Lines, Where Relevant
Examiner Cite Initials • No.1		Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear		
		US-4,855,285	08-1989	Stevens			
		US- 5,994,126	11-1999	Steinman et al.			
		US- 6,150,500	11-2000	Salemo			
		US- 2004/0208885 A1	10-2004	Khan et al.			
		US- 6,844,315	01-2005	Khan et al.			
		US- 2005/0037430 A1	02-2005	Khan et al.	Duplicate Citatio		
		US-					
		US-					
······		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					

FOREIGN PATENT DOCUMENTS						
Examiner	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°
						

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction 33 of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name J. Dunston

Attorney Docket Number 2183-5223US

(use as many sheets as necessary)

Sheet 4 of 14

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		CJI et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, Vol. 286.					
		DWINNBLL et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.					
		KALNS et al., Brichem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.					
		KALNS et al., Biochem. Riophys. Res. Comm., 2002, pp. 41-44, Vol. 292.					
	Merck Index, 17th ed. 1999, pp. 145-1146, 1841-1848, 2539, 2551.						
		Merriam-Webster Medical Dictionary, 1994, p. 82.					
		MOAYERI et al., Journal of Clinical Investigation September 2003, pp. 670-82, Vol. 112, No. 5.					
		NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.					
		PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462. Duplicate Citations					

Examiner	/Jennifer Dunston/ (05/18/2007)	Date
Signature		Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Index the Parawork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et. al.

Group Art Unit 1632 1636

Examiner Name T. Mickelvey J. Dunston

(use as many sheets as necessary)

Sheet 5 of 2 14 Attorney Docket Number 2183-5223US

		Document Number		Name of Patentee or Applicant of		
Examiner Initials *	Cite No. ¹	Cite Publication Date		Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		OC-4,977,244	12-11-1990	Muchmore et al.		
		US- 5,674,275	10-14-1997	Lunardi-Iskandar et al.		
		US- 5,877,148	03-02-1999	Lunardi-Iskandar et al.		
		US- 5,958,413	09-28-1999	Anagnostopulos et al.		
		US- 5,997,871	12-07-1999	Gallo et al.		
		US- 6,319,504 B1	11-20-2001	Gallo et al.		
		US- 2003/0049273 A1	03-13-2003	Galio et al.		
		US- 6,583,109 B1	08-24-2003	Gallo et al.		
		US- 6,596,688 B1	07-22-2003	Gallo et al.		
		US- 6,620,416 B1	09-18-2003	Gallo et al.		
		US- 2002/0064501	05-30-2002	Khan et al.		
		US- 2002/0041871	04-11-2002	Brugnek		
		US-5,851,997	12-22-1998	Harris		
		US- 6,489,296	12-03-2002	Grinnell et al.	Duplicate Citati	

		FOREIGNE	ATENT DOCU	MENIS	~~~ <u>~~~</u>	
Examiner Initials*	Cite	Foreign Patent Document		Name of Patentee or	Pages, Cohmns, Lines,	
	No.1	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ ⁶
		EP 1 300 418	04-09-2003	Erasmus Universiteit Rotterdam		
		WO 98/35691	08-20-1998	Proscript, Inc.		
		WO 02/085117	10-31-2002	Eisai Co., Ltd.		
		DE 3715662	11-19-1987	The Wellcome Foundation Ltd.		
		DE 19953339	05-17-2001	Goldham Pharma GmbH		
		96/04008	62-15-1996	Government of the United States		
		97/49373	12-31-1997	University of Maryland Biotechnology Institute		
		97/49418	12-31-1997	University of Maryland Biotechnology Institute		
		97/49432	12-31-1997	University of Maryland Biotechnology Institute	Duplicate Ci	tatio

Examiner Signature /Jennifer Dunston/ (05/18/2007)	Date Considered
--	--------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

Complete if Known

10/028,075

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Application Number

Substitute for form 1049A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

December 21, 2001 Filing Date First Named Inventor Khan et. al. 1692 1636 Group Art Unit T. McKelvey J. Dunston **Examiner Name**

(use as many sheets as necessary)

of 14 Sheet

-5223US

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials •	, i (and in the second of the			
		CHRISTMAN et al., Nuclear factor kappaB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intens Care Med, 1998, pp. 1131-38, Vol. 24.		
		JYONOUCHI et al., Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression, J Neuroim., 2001, pp. 170-79, Vol. 120.		
		KANUNGO et al., Advanced Maturation of Heteropneustes Fossilis (Bloch) by Oral Administration of Human Chorionic Gonadotropin, J. Adv. Zool., 1999, pp. 1-5, Vol. 20.		
		ROHRIG et al., Growth-stimulating Influence of Human Chorionic Gonadotropin (hCG) on Plasmodium falciparum in vitro, Zentralblatt Bakt, 1999, pp. 89-99, Vol. 289.		
		TAK et al., NF-kappaB: a key role in inflammatory diseases, J Clin Invest., 2001, pp. 7-11, Vol. 107.		
		TAN et al., The role of activation of nuclear factor-kappa B of rat brain in the pathogenesis of experimental allergic encephalomyelitis, Acta Physiol Sinica, 2003, pp. 58-64, Vol. 55.		
		TOVEY et al., Mucosal Cytokine Therapy: Marked Antiviral and Antitumor Activity, J. Interferon Cytokine Res., 1999, pp. 911-21, Vol. 19.	• •	
		MUCHMORE et al., Immunoregulatory Properties of Fractions from Human Pregnancy Urine: Evidence that Human Chorionic Gonadotropin is not Responsible, The Journal of Immunology, March 1997, pp. 881-86, Vol. 118, No. 3.		
		MUCHMORE et al., Purification and Characterization of a Mannose-Containing Disaccharide Obtained from Human Pregnancy Urine, Journal of Experimental Medicine, December 1984, pp. 1672-85, Volume 160.		

_			Dupilicate Citations
Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Tiese the Paperwork Respection Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit 1636

Examiner Name J. Dunston

(use as many sheets as necessary)

Sheet 7 of 2 14 Attorney Docket Number 2183-5223US

<u>-</u> :		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials •	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		KNDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review 2002, pp. 472-499, Vol. 7, No. 6.	
		KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.	
		LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.	
		MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.	
		MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.	
		MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappeB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.	_
		NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.	
		SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.	
		TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.	
		WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neurophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.	
		YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury in cats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	

		Duplicate Citations
Examiner	/Jennifer Dunston/ (05/18/2007)	Date .
Signature	, , , , , , , , , , , , , , , , , , , ,	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

OIP

DEC 11

PTO/SB/08A (08-00)

Appro or use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

NF	ORN	IATIO	N D	ISCL	osu	RE
2	ATER	IATIO	RV	ADDI	ICA	NT

NI

Application Number 10/028,075

Filing Date 12/21/2001

First Named Inventor Khan et al.

(use as many sheets as necessary)

of

Group Art Unit

Examiner Name

To be assigned 1636

Te-be assigned J. Dunston

Attorney Docket Number

2183-5223US

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication of Pages, Columns, Lines, Where Relevant Name of Patentee or Applicant Cite No.1 Examiner Passages or Relevant Kind Code² of Cited Document Cited Document Initiats * Number Figures Appear MM-DD-YYYY (if known) Duplicate Citation 0,040,504 Oallo et al. 11-20-2001 -

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	0.00	For	eign Patent D	ocument	Name of Patentee	Date of Publication of	Pages, Columns, Lines,		
	Cite No.1	Office ³	Number ⁴	Kind Code ⁶ (If known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te	
				·			•		
		ļ							
		 	1						
	•								

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known
INFORMATION BIOOLOGUEE	Application Number	10/028,075
STATEMENT BY APPLICANT	Filing Date	12/21/2001
STATEMENT BY APPLICANT	First Named Inventor	Khan et al.
DEC - E	Group Art Unit	To be assigned 1636
DEC (usames many sheets as necessary)	Examiner Name	To be assigned J. Dunston
Sheet 2 , / 9 of 2 14	Attorney Docket Number	2183-5223US

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		CONNELLY et al., Biphasic Regulation of NF-kB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-81, 166, The American Association of Immunologists, USA.			
•		FRIEDLANDER, Tackling anthrax, Nature, November 8, 2001, pp. 160-61, Vol. 414.			
		MEDZHITOV, Toll-like Receptors and Innate Immunity, Nature Reviews/Immunology, November 2001, pp. 135-45, Vol. 1.			
		Duplicate Citations			
·					

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	
3.3.		The second secon	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

()

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

10

.

14

	Complete if Known
Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1636
Examiner Name	T. McKelvey J. Dunston
Attorney Docket Number	2183-5223US

			U.S. PATENT D	OCUMENTS		
	<u> </u>	Document Number	Publication Date	Name of Patentee or Applicant of	Boom Columns Lines	Where Belgins
Examiner Initials *	Cite No. ¹	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Pages, Columns, Lines, Passages or R Figures Ap	elevant pear
	}	U3-0,727,227	04-27-2004		Duplicate	Citatio
		US-				
		US-				
	1	US-				
		US-				
	1	US-				
		US-			}	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FUREIGN P	ATENT DOCU	MFW12		
Examiner Cite	Cite	ite Foreign Patent Document	DAVIS DUS	Name of Patentee or	Pages, Columns, Lines,	
Initials*	Initials No. Country Code - Number -	Country Code ³ - Number ⁴ - Kind Code ³ (if known)	- Number ⁴ - Kind Code ³ (if known) Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T
				Obschestvo S		
				Ogranichennoi Otvetstvennostiiu		
····		WO 01/00067	- 04-20-2001	"Klinika Instituta	Duplicate	
				Bioregulyatsii I Gerontologii"	Citation	
						
			+			
			+		1	
			<u> </u>			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known 10/028,075 **Application Number** INFORMATION DISCLOSURE December 21, 2001 Filing Date STATEMENT BY APPLICANT Khan et al. First Named Inventor **Group Art Unit** 1636 T. McKelvey J. Dunston (use as many sheets as necessary) **Examiner Name** 2183-5223US Attomey Docket Number Sheet

Examiner Initials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		KACHRA et al., "Low Molecular Weight Components but Not Dimeric HCG Inhibit Growth and Down-Regulate AP-1 Transcription Factor in Kaposi's Sarcoma Cells," Endocrinology, 1997, pp. 4038-4041, vol. 138, no. 9.	
		KHAVINSON et al., "Mechanisms Underlying Geroprotective Effects of Peptides," Bulletin of Experimental Biology and Medicine, January 2002, pp. 1-5, Vol. 133, No. 1.	
		KHAVINSON et al., "Peptide Promotes Overcoming of the Division Limit in Human Somatic Cell," Bulletin of Experimental Biology and Medicine, May 2001, pp. 503-506, Vol. 137, No. 5.	
		MOROZOV et al., "Natural and Synthetic Thymic Peptides as Therapeutics for Immune Dysfunction," Int. J. Immunopharmac., 1997, pp. 501-505, Vol. 19, No. 9/10.	
		KHAVINSON et al., "Inductive Activity of Retinal Poptides," Bulletin of Experimental Biology and Medicine, November 2002, pp. 482-484, Vol. 134, No. 5.	
		KHAVINSON et al., "Effects of Short Peptides on Lymphocyte Chromatin in Senile Subjects," Bulletin of Experimental Biology and Medicine, January 2004, pp. 78-81, Vol. 137, No. 1.	
		KHAVINSON et al., "Effects of Livagen Peptide on Chromatin Activation in Comphocytes from Old People," Bulletin of Experimental Biology and Medicine, October 2002, pp. 389-392, Vol. 134, No. 4.	
		KHAVINSON et al., "Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells," Bulletin of Experimental Biology and Medicine, June 2003, pp. 590-592, Vol. 135, No. 6.	
		IVANOV et al., "Hemoglobin as a Source of Endogenous Bioactive Peptides: The Concept of Tissue-Specific Peptide Pool," Biopolymers, 1997, pp. 171-188, Vol. 39.	
		KHAVINSON et al, Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.	,

Examiner	/Jennifer Dunston/ (05/18/2007)	Date	
Signature	/Jennier Dunston/ (UJ/10/2007)	Considered	2 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/028,075

Filing Date December 21, 2001

First Named Inventor Khan et al.

Group Art Unit To-be assigned 1636

Examiner Name To-be assigned J. Dunston

(use as many sheets as necessary)

12 of 2 14 Attorney Docket Number 2183-5223US

	1		U.S. PATENT D	· · · · · · · · · · · · · · · · · · ·	
Examiner Cite	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan
Initials *	No.1	Number - Kind Code (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
		US-			
		US-	,	,	
		US-			

		FOREIGN P	ATENT DOCU	MENTS		
Examiner Cite	Cite Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
Initials*	laisiatat Na t	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date Y - Kind Code' (If known) MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁴
	-	WO 89/59617	11-25-1999	Erasmus Universiteit		
		WO 97/49721	12-31-1997	University of Win, lead D1	plicate Cita	tion
			,			
			·			
		·				
			T			

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

4 APPLICANT

(use as many sheets as necessary)

Examiner

Signature

	Complete if Known		
Application Number	10/028,075		
Filing Date	December 21, 2001		
First Named Inventor	Khan et al.		
Group Art Unit	To be assigned 1636		
Examiner Name	Tobe assigned J. Dunston		
Attorney Docket Number	2183-5223US		

Examiner Cite Initials • No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		PCT International Search Report, PCT/NL01/00259, dated December 18, 2001, 3 pages.				
		PCT International Preliminary Examination Report, PCT/NL99/00313, dated July 21, 2000, 6 pages.				
		PCT International Search Report, PCT/EP99/00313, dated November 29, 1999, 3 pages.				
		Lang et al., "Induction of apoptosis in Kaposi's sarcoma spindle cell cultures by the cubunits of human chorionic gonadotropin", AIDS 1997, Vol. 11, No. 11, pp.1333-1340.	-			
		Iskandar et al., "Effects of a urinary factor from women in early pregnancy on HIV-1. SIV and associated disease", Nature Medicine, April 1998, Vol. 4, No. 4, pp. 428-434.				
		Duplicate Citations				
			<u> </u>			

Date

Considered

/Jennifer Dunston/ (05/18/2007)



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apr of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 1

Complete if Known				
Application Number	10/028,075			
Filing Date	December 21, 2001			
First Named Inventor	Khan et al.			
Group Art Unit	1636			
Examiner Name	T. McKelvey J. Dunston			
Attorney Docket Number	2183-5223US			

		Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Cite Initials * No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
		US-5,380,668	01-10-1995	Herron	
		US- 2003/0186244 A1	10-02-2003	Margus et al.	
	 	US- 2003/0 N 1733 A1	06-19-2003	Khan et al.	
		US- 2003/0119720-41	06-26-2003	Khan et al.	
		US- 2002/0064501 A1	05-30-2002	Khan et al.	
		US- 2003/0166556 A1	09-04-2003	Khan et al.	
		US- 2003/0215434 A1	11-20-2003	Khan et al.	
		US- 2003/0219425 A1	11-97-2003	Khan et al.	
		US- 2003/0220257 A1	11-27-2063	Benner et al.	<u> </u>
		US- 2003/0220258 A1	11-27-2003	Benner et al.	
		US- 2003/0220259 A1	11-27-2003	Benner et al.	
		US- 2003/0220260 A1	11-27-2003	Khan et al.	
		US- 2003/0220261 A1	11-27-2003	Kinan et al.	
		US- 2003/0224995 A1	12-04-2003	Khan et al	
		US- 2004/0013661 A1	01-22-2004	Wensvoort et al.	Duplicate Citation
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Cite Initials* No.	Cita	Foreign Patent Document	D. A. Francis	Name of Patentee or	Pages, Columns, Lines,	
		Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY		Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
		WO 03/030303 A3	04.10.2003	Erasmus Universiteit Rotterdam	Duplicate Ci	tatio
						····

Examiner Signature	/Jennifer Dunston/ (05/18/2007)	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.